CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central ...
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biotech focused on advancing therapies for serious diseases in neurology and oncology, particularly brain and central nervous system cancers. The company is headquartered in Houston, Texas, and operates with a small team (reported full-time employee count is 8), which is typical for ...CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biotech focused on advancing therapies for serious diseases in neurology and oncology, particularly brain and central nervous system cancers. The company is headquartered in Houston, Texas, and operates with a small team (reported full-time employee count is 8), which is typical for early-stage development companies that rely on clinical execution, research partnerships, and outsourced or collaborative resources to progress investigational programs.
At the center of CNS Pharmaceuticals’ pipeline is Berubicin, an anthracycline investigational therapy being evaluated in Phase I and Phase II clinical trials for glioblastoma multiforme (GBM), an aggressive form of brain cancer. The company’s strategy emphasizes building and executing a higher-value pipeline in neurology and oncology, which includes advancing development plans and leveraging scientific and clinical infrastructure necessary for oncology trials (e.g., trial design, patient recruitment, manufacturing/CMC coordination, and regulatory interactions).
To support its research and development efforts, CNS Pharmaceuticals has entered into multiple strategic relationships. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC, as well as a development agreement with WPD Pharmaceuticals Inc. and a collaboration with Reata Pharmaceuticals, Inc. Such agreements can broaden access to technology, expertise, and clinical capabilities while potentially reducing time-to-progress and capital intensity compared with building all capabilities internally.
From a cost and operations perspective, a clinical-stage oncology developer typically faces high fixed and variable expenses tied to clinical trial execution (site costs, monitoring, labs, patient-related expenses), drug supply/manufacturing, regulatory and quality systems, and ongoing R&D overhead. The provided financial snapshot signals an early development-stage profile, including negative returns on assets/equity and negative free cash flow measures (i.e., ongoing reinvestment and/or reliance on capital raises rather than current profitability).
Key leadership includes Rami Levin, President and Chief Executive Officer. Other executive leadership is described through company materials and investor communications (e.g., a CFO and a medical/clinical leadership team), reflecting the multidisciplinary nature of bringing therapeutics from investigational formulation through clinical evaluation. Overall, CNS Pharmaceuticals’ near-term “wish” or objective is likely to successfully progress its lead program(s) through clinical milestones, strengthen its pipeline value, and convert clinical and partnering progress into continued financing and potential future commercialization pathways if therapeutic efficacy and safety support advancement.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-15.9M
-6.7%
+47.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-13.8M
+19.2%
+23.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
7.3%
+37.6%
-100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.98x
-42.4%
+563.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
